

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6874222

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
IRISYS, LLC	08/13/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	IRISYS, INC.
<b>Street Address:</b>	6828 NANCY RIDGE DRIVE, SUITE 100
<b>City:</b>	SAN DIEGO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16331258
<b>Application Number:</b>	17174291
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(858)314-1501
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(858) 314-1539
<b>Email:</b>	lmjaramillo@mintz.com, IPDocketingBOS@mintz.com
<b>Correspondent Name:</b>	MINTZ/SAN DIEGO OFFICE
<b>Address Line 1:</b>	ONE FINANCIAL CENTER
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02111
<b>ATTORNEY DOCKET NUMBER:</b>	047022-501C01US
<b>NAME OF SUBMITTER:</b>	LUIS JARAMILLO, PATENT SPECIALIST
<b>SIGNATURE:</b>	/Luis Jaramillo/
<b>DATE SIGNED:</b>	08/19/2021
<b>Total Attachments: 3</b>	
source=047022-501_Assignment-IrisysLLC_to_IrisysInc#page1.tif	
source=047022-501_Assignment-IrisysLLC_to_IrisysInc#page2.tif	
source=047022-501_Assignment-IrisysLLC_to_IrisysInc#page3.tif	

## ASSIGNMENT

**Irisys, LLC** having a principal place of business at **6828 Nancy Ridge Drive, Suite 100, San Diego, CA 92121** (“Assignor”), is the owner of the entire right, title, and interest in and to certain inventions and improvements entitled “LIPOSOMAL ANTICANCER COMPOSITION” that is the subject matter of the Letters Patent and applications for Letters Patent set forth in Exhibit A.

For good and valuable consideration, the receipt and sufficiency of which Assignor acknowledges, Assignor agrees, as of the Date signed below, to assign, transfer, convey, and sell to **Irisys, Inc.** having a principal place of business at **6828 Nancy Ridge Drive, Suite 100, San Diego, CA 92121** (“Assignee”), the entire right, title, and interest in and to:

- (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the patent applications set forth in Exhibit A, implicitly or explicitly;
  - (b) the patent applications set forth in Exhibit A, the right to claim priority to the patent applications set forth in Exhibit A, all applications based in whole or in part upon the patent applications set forth in Exhibit A, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the patent applications set forth in Exhibit A;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
  - (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee’s own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.

- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside my signature on behalf of Assignor: **Irisys, LLC**

August 13, 2021  
Date

DocuSigned by:  
Gerald J. Yakatan  
Signature

Gerald Yakatan  
Name

Chief Executive Officer  
Title

ASSIGNEE hereby acknowledges receipt of the entire right, title and interest in and to the PATENTS AND PATENT APPLICATIONS.

Assignee: **Irisys, Inc.**

August 13, 2021  
Date

DocuSigned by:  
Gerald J. Yakatan  
Signature

Gerald Yakatan  
Name

Chief Executive Officer  
Title

**Exhibit A**

<b>Country</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Patent Grant Date</b>
United States	16/331,258	March 7, 2019	11,033,520	June 15, 2021
United States	17/174,291	February 11, 2021		
Australia	2017324718	September 1, 2017		
Canada	3,036,235	September 1, 2017		
China	201780069799.1	September 1, 2017		
Europe	17849367.2	September 1, 2017		
Hong Kong	19129371.1	September 1, 2017		
India	201947013282	September 1, 2017		
Japan	2019-535188	September 1, 2017		
Korea	10-2019-7010003	September 1, 2017		
Mexico	MX/a/2019/002733	September 1, 2017		
New Zealand	751244	September 1, 2017		
Russia	2019110275	September 1, 2017		
Singapore	11201902101S	September 1, 2017		
PCT	PCT/US2017/49968	September 1, 2017		